Evidence map›Paper›PMID 42519776›Full record

ArticleFrontiers in medicine2026

MiR-144-3p regulates cell proliferation and apoptosis in renal ischemia-reperfusion injury by targeting EZH2.

Lifeng Zhang, Fuxin Zheng, Xin Li, Rui Min, Yaping Yang, Wei Jiang, Lei Lyu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lifeng Zhang *Department of Urology, Ezhou Centre Hospital, Ezhou, China.
Fuxin Zheng *Department of Urology, Wuhan No.1 Hospital (Traditional Chinese and Western Medicine Hospital of Wuhan), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xin LiDepartment of Urology, Wuhan No.1 Hospital (Traditional Chinese and Western Medicine Hospital of Wuhan), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Rui MinDepartment of Urology, Wuhan No.1 Hospital (Traditional Chinese and Western Medicine Hospital of Wuhan), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yaping YangDepartment of Urology, Ezhou Centre Hospital, Ezhou, China.
Wei JiangDepartment of Urology, Ezhou Centre Hospital, Ezhou, China.
Lei LyuDepartment of Urology, Wuhan No.1 Hospital (Traditional Chinese and Western Medicine Hospital of Wuhan), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal ischemia-reperfusion injury (IRI) is a leading cause of acute kidney injury, with limited effective therapeutic options. While microRNAs (miRNAs) play crucial roles in regulating various diseases, including renal IRI, their specific targets and mechanisms remain elusive. In this study, hypoxia/reoxygenation (H/R) significantly promoted apoptosis in both NRK-52E and HK-2 cells, accompanied by a marked downregulation of miR-144-3p in both H/R-treated cells and the kidneys of mice subjected to ischemia/reperfusion (I/R) injury. Moreover, miR-144-3p overexpression enhanced cell viability under H/R conditions, as evidenced by the results of MTT assays. Dual-luciferase reporter assays identified

Indexed as

apoptosisBaxCaspase-3EZH2ischemia-reperfusion injurymiR-144-3p

Identifiers

PMID42519776
PMCPMC13383657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.